- Home
- BMEA vs PYXS Comparison
BMEA vs PYXS Comparison
Compare BMEA & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- PYXS
- Stock Information
- Founded
- BMEA 2017
- PYXS 2018
- Country
- BMEA United States
- PYXS United States
- Employees
- BMEA N/A
- PYXS N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- PYXS Health Care
- Exchange
- BMEA Nasdaq
- PYXS Nasdaq
- Market Cap
- BMEA 65.8M
- PYXS 64.4M
- IPO Year
- BMEA 2021
- PYXS 2021
- Fundamental
- Price
- BMEA $1.73
- PYXS $1.08
- Analyst Decision
- BMEA Strong Buy
- PYXS Strong Buy
- Analyst Count
- BMEA 11
- PYXS 6
- Target Price
- BMEA $27.60
- PYXS $9.20
- AVG Volume (30 Days)
- BMEA 713.5K
- PYXS 520.0K
- Earning Date
- BMEA 05-05-2025
- PYXS 05-20-2025
- Dividend Yield
- BMEA N/A
- PYXS N/A
- EPS Growth
- BMEA N/A
- PYXS N/A
- EPS
- BMEA N/A
- PYXS N/A
- Revenue
- BMEA N/A
- PYXS $16,146,000.00
- Revenue This Year
- BMEA N/A
- PYXS N/A
- Revenue Next Year
- BMEA N/A
- PYXS N/A
- P/E Ratio
- BMEA N/A
- PYXS N/A
- Revenue Growth
- BMEA N/A
- PYXS N/A
- 52 Week Low
- BMEA $1.53
- PYXS $0.83
- 52 Week High
- BMEA $13.43
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- BMEA 41.85
- PYXS 53.61
- Support Level
- BMEA $1.61
- PYXS $1.05
- Resistance Level
- BMEA $2.30
- PYXS $1.33
- Average True Range (ATR)
- BMEA 0.20
- PYXS 0.10
- MACD
- BMEA -0.00
- PYXS 0.01
- Stochastic Oscillator
- BMEA 21.74
- PYXS 38.24
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.